Difference between revisions of "Temsirolimus (Torisel)"
m |
m |
||
Line 25: | Line 25: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*2007-11-19: Initial authorization | *2007-11-19: Initial authorization | ||
+ | ==History of changes in Health Canada indication== | ||
+ | *2007-12-21: Initial notice of compliance | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
*2010-07-23: Initial approval for the treatment of unresectable or metastatic [[renal cell carcinoma]]. | *2010-07-23: Initial approval for the treatment of unresectable or metastatic [[renal cell carcinoma]]. | ||
Line 50: | Line 52: | ||
[[Category:EMA approved in 2007]] | [[Category:EMA approved in 2007]] | ||
[[Category:FDA approved in 2007]] | [[Category:FDA approved in 2007]] | ||
+ | [[Category:Health Canada approved in 2007]] | ||
[[Category:PMDA approved in 2010]] | [[Category:PMDA approved in 2010]] |
Revision as of 22:12, 14 June 2023
General information
Class/mechanism: mTOR (mammalian target of rapamycin) inhibitor. mTOR inhibition by temsirolimus interferes with the ability of mTOR to phosphorylate downstream targets in the PI3 kinase/AKT pathway, such as p70S6k and the S6 ribosomal protein. Temsirolimus has also been observed to reduce levels of VEGF (vascular endothelial growth factor) and hypoxia-inducible factors HIF-1 and HIF-2 alpha.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established (work in progress)
Diseases for which it is used
Patient drug information
- Temsirolimus (Torisel) package insert[1]
- Temsirolimus (Torisel) patient drug information (Chemocare)[4]
- Temsirolimus (Torisel) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2007-05-30: Initial FDA approval for the treatment of advanced renal cell carcinoma. (Based on ARCC)
History of changes in EMA indication
- 2007-11-19: Initial authorization
History of changes in Health Canada indication
- 2007-12-21: Initial notice of compliance
History of changes in PMDA indication
- 2010-07-23: Initial approval for the treatment of unresectable or metastatic renal cell carcinoma.
Also known as
- Code name: CCI-779
- Brand name: Torisel
References
- Drugs
- Intravenous medications
- MTOR inhibitors
- CNS lymphoma medications
- Diffuse large B-cell lymphoma medications
- Follicular lymphoma medications
- Mantle cell lymphoma medications
- Renal cell carcinoma medications
- Endometrial cancer medications
- EMA approved in 2007
- FDA approved in 2007
- Health Canada approved in 2007
- PMDA approved in 2010